First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

Summary by AI BETAClose X

BioNTech and Bristol Myers Squibb announced encouraging interim Phase 2 data for their bispecific antibody pumitamig (BNT327/BMS986545) plus chemotherapy in patients with extensive-stage small cell lung cancer. The data revealed a 76.3% confirmed objective response rate and a 100% disease control rate. Patients achieved a median progression-free survival of 6.8 months. The mean best percentage change in tumor size showed a tumor shrinkage of 56.7% with 89.5% of patients achieving early tumor shrinkage. The treatment demonstrated a manageable safety profile with a 14% discontinuation rate. These findings support the dose selection for the ongoing pivotal Phase 3 ROSETTA LUNG-01 trial.

Disclaimer*

UK 100

Latest directors dealings